Dr. Wiseman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Mayo Clinic, Dept Nuc Med
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
University of WashingtonResidency, Nuclear Medicine, 1989 - 1992
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1987 - 1989- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1983 - 1985
University of Utah School of MedicineClass of 1983
Certifications & Licensure
IA State Medical License 2013 - 2026
AZ State Medical License 2013 - 2025
MN State Medical License 1992 - 2025
WI State Medical License 2014 - 2025
FL State Medical License 2013 - 2022
GA State Medical License 2013 - 2016
WA State Medical License 1990 - 1992- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Nuclear Medicine Nuclear Medicine
Clinical Trials
- Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma Start of enrollment: 2003 Sep 01
Publications & Presentations
PubMed
- 220 citationsA phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasiaRuben A. Mesa, David P. Steensma, Animesh Pardanani, Chin Yang Li, Michelle A. Elliott
Blood. 2003-04-01 - 212 citationsSafety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.Thomas E. Witzig, C.A. White, Leo I. Gordon, Gregory A. Wiseman, Christos Emmanouilides
Journal of Clinical Oncology. 2003-04-01 - 81 citationsSubsequent Chemotherapy Regimens Are Well Tolerated After Radioimmunotherapy With Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin’s LymphomaStephen M. Ansell, Kay M. Ristow, Thomas M. Habermann, Gregory A. Wiseman, Thomas E. Witzig
Journal of Clinical Oncology. 2002-09-15
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
